JHP Pharmaceuticals has entered into an agreement with an undisclosed biotechnology company to provide clinical supplies for late-phase trials. JHP will manufacture the product at its Rochester, MI facility, which provides clinical batch production to commercialization and offers services including regulatory, analytical methods development, package engineering, stability testing and validation.
Stuart Hinchen, JHP’s chief executive officer, said, “Our record of cGMP compliance, driven by experienced Quality and Regulatory Teams, continues to be one of the key reasons customers choose JHP. Additionally, both new and established customers recognize our approach to ongoing investment in people and facilities. Our use of disposable product contact equipment is another leading factor in the selection process. JHP’s strategic use of disposables provides our customers with manufacturing process efficiencies that result in reduced cycle time.”